All News

Year in Review #ACR22 Pre-expos PPx for COVID! Tix-Cil (Evusheld): risk reduction 77% Cardiac AES 0.6% vs placebo 0.2% Only 3.3% were on immunosuppression But Israeli study with immunosuppressed: 92% half as likely to be hospitalized or die 1/2 less infections @RheumNow

Ab1291 #ACR22: 🔥Ignite🔥 @DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.8, sensitivity 0.39 - better than existing practice (PPV 0.77) Predictors: age, diagnoses, medications, RAPID3, provider preference for 💻🩺 3 mo pilot program predictive @RheumNow https://t.co/Iey87SVGv4

Very important point about statin induced myopathy by Dr. Christopher-Stine. If 1) history of statin exposure, 2) typical symptoms of myositis 3) HMGCR ab positive — do NOT need biopsy and can treat as statin associated necrotizing autoimmune myopathy! @RheumNow #ACR22 https://t.co/VHxPRkCWwj

Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22 https://t.co/2IikApUdvE https://t.co/16ggVScs3a

Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrop…

SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO

Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis wit…

Do you check ANCAs in your ILD pts? Abs 0438 at #ACR22 suggests you should! @RheumNow https://t.co/W8rRAdWFQh https://t.co/RQfcQQUVzI

Characterization of Interstitial Lung Disease in the Presence of Antineutrophil…

Headed to the #ACR22 Fellows in Training (FIT) session for a round table on keeping up with the medical literature! As usual, updated handout for this year 🤓 @MithuRheum Wish I had thought to ask you for help w/my graphics-game! Not my strength hahaha #ACRAmbassador https://t.co/Tg4ZT262rU

Very cool initiative @Robsonjo4 1. I love patient reported outcomes (PROs) 2. I think we under-appreciate how much steroids affect our patients quality of life Looking forward to seeing this live! #ACR22 #Vasculitis22 @RheumNow https://t.co/1akO1k7VgU

Interesting study about causes of death in GCA I never know what to make of these; our pts typically die of the usual things (cancer, CVD) and have increased risks of infection (due to treatment) Is there USA data about this? #ACRAmbassador #ACR22 https://t.co/ZMOSD7lYGL

Regional Winners (people's choice award goes to North America tumoral calcinosis) #ACR22 Image Competition @rheumnow https://t.co/y7dDHc75PQ

“I don’t live in an igloo, I don’t have a dog sled, and yes we do have daylight some times of the year – Dr. John Botson (from Alaska) answering questions on everyone's mind before he presented the MIRROR RCT study #Plenary1 #ACR22 @rheumnow https://t.co/y23Keeh3r8

What has changed since the 2020 @ACRheum #reproductive guidelines? Abstract #1717 425 SLE/RA patients: 📍 significant improvement in pre-#pregnancy counseling and discussions in reproductive goals 📍No improvements in birth control use or documentation

#RheumPearls: Check APLs in all SLE pts because they influences contraceptive choice, postpartum/surgery anticoag prophylx, and HRT counseling Dr. J Kolfenbach #ACR22 @rheumnow https://t.co/Hnrh4NhmBj

We share our vision of what rheumatologists should be considering thinking and doing regarding COVID-19 in our immunocompromise patients. Would love your reactions @CCalabreseDO @BetsyKirch @DrPujaMehta1 @alhkim @drdavidliew @philipcrobinson #ACR22 https://t.co/OpmoEOXWmL

https://twitter.com/acr_journals/status/1591172806087016448

This year, as every year, at ACR (and EULAR) I am amazed by some of what are oral presentations vs what is in the posters. Please check out the poster sessions, there are some absolute gems in there! I will amplify the ones I find that I feel competent to discuss #ACR22

Primary care provider education can improve rheumatology care: ➤ Post-training ratings in confidence and knowledge improved compared to baseline ➤ Gives me confidence for my own local programme RheumACaN for GPs,PCPs Mandal J 0005 https://t.co/MCb7QTcYsL #ACR22 @RheumNow https://t.co/sTYFtbbvtT

The Rheumatology Access Expansion (RAE) Initiative: Improving Rheumatoid Arthri…

HCQ tx thresholds study by Prof Garg: 🔸HCQ >=500ng/ml: good threshold to detect adherence 🔸HCQ 750-1000ng/ml: effective thresholds to prevent flares 🔸CKD>=2: 4x ⬆️odds of HCQ>1500ng/ml (supraTx! dose adj.) Interesting data. Game changing?🧐 #ACR22 @RheumNow ABST#0344 #ACRBest https://t.co/GxlucrTeE5

Interesting data on TNFi use in ankylosing spondylitis. Early TNFi use, compared to no TNFi associated with higher CVD, stroke and MACE. @rheum_cat any thought on why? and why there were so many non-TNFi users (15k vs. 2k)? Abs#0415 @RheumNow #ACR22 https://t.co/PVkt8gPHFW

ACEi improve survival in SSc Renal Crisis ◦ Routine use of ACEi as prophylaxis is a myth ◦ ACEi prophylaxis may set up a chronic, less reversible process ◦ Best used in high BP, low creatinine - bring on the ACEi then John Stone, Secrets and Pearls #ACR22 @RheumNow https://t.co/3leCEmtaj1

Add GPA to the list of causes of dacryoadenitis (inflammation of the lacrimal gland, main or accessory). Differential diagnoses of dacryoadenitis: ● Sjogren's ● Sarcoidosis ● IgG4 RD ● AL Amyloidosis ● GPA John Stone, Secrets and Pearls #ACR22 @RheumNow https://t.co/dvXbkpfcAq

Topics

All News

Do you get our email newsletter?